The health care industry has come under scrutiny lately, thanks to the scandal over the sale of $6 billion worth of highly toxic drugs to an Indian pharmaceutical company.
But how much is too much?
In this episode, I’ll tell you.
I’m joined by Michael P. Shiffrin, a senior health care economist at the RAND Corporation, and Mark L. Bittman, an economist at Johns Hopkins Bloomberg School of Public Health.
You can listen to the episode on HealthDay.com.
Free View in iTunes
RED BULL DISCOVERY AND THE ROLE OF SENSITIVITY IN SOCIAL MEDIA
Fox Sports: Fox Sports’ new ad buys are ‘very impressive’